Alli (orlistat 60 mg) is the only FDA-approved over-the-counter weight loss aid that works locally in the digestive system to prevent the absorption of about 25% of dietary fat. It is designed for use in adults with a body mass index (BMI) of 25 or higher, as part of a reduced-calorie, low-fat diet and exercise program. By blocking fat absorption, Alli supports sustainable weight management when used as directed under appropriate medical guidance.

Features

• Contains 60 mg of orlistat per capsule
• Non-systemic action; works in the digestive tract
• Prevents absorption of approximately 25% of dietary fat
• Gluten-free formulation
• Available without prescription for adult use
• Packaged with a personalized online support plan

Benefits

• Supports clinically meaningful weight loss when combined with lifestyle changes
• Helps users develop healthier eating habits by reinforcing low-fat dietary choices
• Provides a non-stimulant alternative to other weight management supplements
• Encourages long-term weight maintenance through behavioral adaptation
• Reduces calorie intake from fat without affecting carbohydrate or protein absorption
• Empowers users with educational resources and tracking tools

Common use

Alli is indicated for weight management in overweight adults (BMI ≥25) as an adjunct to a reduced-calorie, low-fat diet. It is commonly used by individuals who have struggled to lose weight through diet and exercise alone, particularly those seeking a pharmacologically supported approach to fat restriction. The medication is often incorporated into structured weight loss programs under healthcare provider guidance, with typical treatment duration ranging from several months to ongoing use based on individual progress and goals.

Dosage and direction

The recommended dosage is one 60 mg capsule taken three times daily with each main meal containing fat (up to 15 grams of fat per meal). The capsule should be taken during the meal or up to one hour after eating. If a meal is missed or contains no fat, the dose of Alli should be omitted. The medication works optimally when dietary fat intake is distributed evenly across meals. Patients should maintain a nutritionally balanced, reduced-calorie diet containing approximately 30% of calories from fat. Daily multivitamin supplementation is recommended due to potential fat-soluble vitamin malabsorption.

Precautions

Patients should undergo health screening before starting Alli, particularly regarding renal function, thyroid status, and cardiovascular risk factors. Regular monitoring of weight, BMI, and metabolic parameters is advised during treatment. Use with caution in patients with history of hyperoxaluria or calcium oxalate nephrolithiasis, as orlistat may increase urinary oxalate excretion. Patients should be advised about the potential for gastrointestinal effects and the importance of adhering to a low-fat diet to minimize these effects. Periodic evaluation of vitamin levels (A, D, E, K) is recommended during prolonged use.

Contraindications

Alli is contraindicated in patients with chronic malabsorption syndrome or cholestasis. It should not be used during pregnancy or breastfeeding. Use is prohibited in patients with organ transplant due to potential interactions with immunosuppressive medications. Alli is contraindicated in patients taking cyclosporine or with known hypersensitivity to orlistat or any component of the formulation. It should not be used by individuals with anorexia nervosa or bulimia.

Possible side effects

The most common side effects are gastrointestinal and related to fat malabsorption, including:

• Oily spotting
• Flatus with discharge
• Fecal urgency
• Fatty/oily stool
• Oily evacuation
• Increased defecation
• Fecal incontinence

These effects are generally mild to moderate, decrease over time with continued use, and can be minimized by adhering to a low-fat diet. Less common side effects may include tooth/gum discomfort, headache, upper respiratory infection, and back pain. Rare cases of severe hepatotoxicity have been reported with orlistat use.

Drug interactions

Alli may reduce absorption of fat-soluble vitamins (A, D, E, K) and beta-carotene. Patients should take a multivitamin supplement containing these vitamins at least 2 hours before or after Alli administration. Orlistat may affect the absorption of:

• Cyclosporine (contraindicated)
• Amiodarone
• Levothyroxine (dose separation required)
• Warfarin (monitor INR closely)
• Antiepileptic medications
• Antiretroviral drugs

Concurrent use with other weight loss medications is not recommended.

Missed dose

If a dose is missed, resume the regular dosing schedule with the next meal. Do not double the dose to make up for a missed dose. The medication should only be taken when consuming a meal that contains fat.

Overdose

There are no reports of serious adverse events from orlistat overdose. Single doses of 800 mg and multiple doses up to 400 mg three times daily have been studied without significant adverse effects. In case of suspected overdose, provide supportive care and monitor for gastrointestinal effects. There is no specific antidote for orlistat overdose.

Storage

Store at room temperature (20-25°C or 68-77°F) in the original container with the cap tightly closed. Keep away from excess heat and moisture. Do not freeze. Keep out of reach of children and pets. Discard any unused medication after the expiration date printed on the packaging.

Disclaimer

This information is for educational purposes only and does not constitute medical advice. Alli should be used under the guidance of a healthcare professional. Individual results may vary. The medication is intended as part of a comprehensive weight management program including diet and exercise. Patients should read the complete product labeling and consult with a healthcare provider before starting treatment, particularly if they have underlying medical conditions or are taking other medications.

Reviews

Clinical studies demonstrate that Alli, when used with a reduced-calorie diet, produces approximately 50% more weight loss than diet alone. In a 6-month study, patients using Alli lost an average of 5-10 pounds more than those using placebo with lifestyle modification. Many users report successful weight management when combining the medication with consistent dietary adherence. Healthcare providers note that patient education about low-fat eating is critical for minimizing gastrointestinal side effects and achieving optimal results. Long-term users often describe improved relationship with food and better understanding of nutritional content.